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Unfortunately an incorrect Table 1 was published. Please
ﬁnd below the correct table.













Median TTP 8.3 months 4.6 months
Patients who had received
prior Antiestrogen
n 84 83





HR-positive n 294 305





HR-unknown n 159 149





TTP, time to progression; CI, conﬁdence interval; HR, hormone
receptor
a Hazard ratios <1.0 indicate superiority for letrozole relative to
tamoxifen
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